Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Dermatology

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 365 articles:
HTML format



Single Articles


    May 2021
  1. ARROYO MUHR LS, Hultin E, Dillner J
    Transcription of Human Papillomaviruses in Non-Melanoma Skin Cancers of the Immunosuppressed.
    Int J Cancer. 2021 May 14. doi: 10.1002/ijc.33683.
    PubMed     Abstract available


    April 2021
  2. SUN Q, Novak D, Huser L, Poelchen J, et al
    FOXD1 Promotes Dedifferentiation and Targeted Therapy Resistance in Melanoma by Regulating the Expression of CTGF.
    Int J Cancer. 2021 Apr 9. doi: 10.1002/ijc.33591.
    PubMed     Abstract available


    March 2021
  3. SONNENBLICK A, Agbor-Tarh D, de Azambuja E, Hultsch S, et al
    STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial.
    Int J Cancer. 2021;148:1529-1535.
    PubMed     Abstract available


    February 2021
  4. BUCCHI L, Mancini S, Crocetti E, Dal Maso L, et al
    Mid-term trends and recent birth-cohort-dependent changes in incidence rates of cutaneous malignant melanoma in Italy.
    Int J Cancer. 2021;148:835-844.
    PubMed     Abstract available


  5. HEIDRICH I, Ackar L, Mossahebi Mohammadi P, Pantel K, et al
    Liquid biopsies: Potential and challenges.
    Int J Cancer. 2021;148:528-545.
    PubMed     Abstract available


    January 2021
  6. SACCHETTO L, Rosso S, Comber H, Bouchardy C, et al
    Skin Melanoma Deaths Within 1 Or 3 Years From Diagnosis In Europe.
    Int J Cancer. 2021 Jan 26. doi: 10.1002/ijc.33479.
    PubMed     Abstract available


  7. MONESTIER S, Dalle S, Mortier L, Dutriaux C, et al
    Effectiveness and Safety of Nivolumab in Patients with Advanced Melanoma: A Multicenter, Observational Study.
    Int J Cancer. 2021 Jan 11. doi: 10.1002/ijc.33467.
    PubMed     Abstract available


  8. PREOBRAZHENSKAYA EV, Shleykina AU, Gorustovich OA, Martianov AS, et al
    Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
    Int J Cancer. 2021;148:203-210.
    PubMed     Abstract available


  9. LAMEIJER JRC, Nederend J, Voogd AC, Tjan-Heijnen VCG, et al
    Frequency and diagnostic outcome of bilateral recall at screening mammography.
    Int J Cancer. 2021;148:48-56.
    PubMed     Abstract available


    November 2020
  10. BRILL R, Uller W, Huf V, Muller-Wille R, et al
    Additive value of Transarterial Embolization to systemic Sirolimus treatment in Kaposiform Hemangioendothelioma.
    Int J Cancer. 2020 Nov 24. doi: 10.1002/ijc.33406.
    PubMed     Abstract available


  11. DELLAC S, Ben-Dov H, Raanan A, Saleem H, et al
    Constitutive low expression of antiviral effectors sensitizes melanoma cells to a novel oncolytic virus.
    Int J Cancer. 2020 Nov 16. doi: 10.1002/ijc.33401.
    PubMed     Abstract available


  12. HEO MJ, Kang SH, Kim YS, Lee JM, et al
    UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis.
    Int J Cancer. 2020;147:2550-2563.
    PubMed     Abstract available


    October 2020
  13. DAI WF, Beca J, Croxford R, Isaranuwatchai W, et al
    Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada.
    Int J Cancer. 2020 Oct 26. doi: 10.1002/ijc.33357.
    PubMed     Abstract available


  14. ZHANG Y, Wang P, Li X, Ning S, et al
    GABC: A Comprehensive Resource and Genome Atlas for Breast Cancer.
    Int J Cancer. 2020 Oct 16. doi: 10.1002/ijc.33347.
    PubMed     Abstract available


  15. YUAN S, Kar S, Vithayathil M, Carter P, et al
    Causal associations of thyroid function and dysfunction with overall, breast and thyroid cancer: A two-sample Mendelian randomization study.
    Int J Cancer. 2020;147:1895-1903.
    PubMed     Abstract available


    September 2020
  16. KINLEN LJ, Gilham C, Ray R, Thomas DB, et al
    Cohabitation, infection and breast cancer risk.
    Int J Cancer. 2020 Sep 27. doi: 10.1002/ijc.33319.
    PubMed     Abstract available


  17. WEITZER J, Castano-Vinyals G, Aragones N, Gomez-Acebo I, et al
    Effect of time of day of recreational and household physical activity on prostate and breast cancer risk (MCC-Spain Study).
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33310.
    PubMed     Abstract available


  18. ONG JS, Derks EM, Eriksson M, An J, et al
    Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33308.
    PubMed     Abstract available


  19. TAN PS, Alsheh Ali M, Eriksson M, Hall P, et al
    Mammography features for early markers of aggressive breast cancer subtypes and tumor characteristics - a population-based cohort study.
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33309.
    PubMed     Abstract available


  20. STALIN J, Traboulsi W, Vivancos-Stalin L, Nollet M, et al
    Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors.
    Int J Cancer. 2020;147:1666-1679.
    PubMed     Abstract available


  21. APOSTOLOU P, Fostira F, Kouroussis C, Kalfakakou D, et al
    BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
    Int J Cancer. 2020;147:1334-1342.
    PubMed     Abstract available


    August 2020
  22. UGALDE-MORALES E, Grassmann F, Humphreys K, Li J, et al
    Association between breast cancer risk and disease aggressiveness: characterizing underlying gene expression patterns.
    Int J Cancer. 2020 Aug 28. doi: 10.1002/ijc.33270.
    PubMed     Abstract available


  23. BOARD R, Smittenaar R, Lawton S, Liu H, et al
    Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018.
    Int J Cancer. 2020 Aug 24. doi: 10.1002/ijc.33266.
    PubMed     Abstract available


  24. WANG F, Meszoely I, Pal T, Mayer IA, et al
    Radiotherapy After Breast Conserving Surgery for Elderly Patients with Early-Stage Breast Cancer: A National Registry Based Study.
    Int J Cancer. 2020 Aug 24. doi: 10.1002/ijc.33265.
    PubMed     Abstract available


  25. SATO M, Onuma K, Domon M, Hasegawa S, et al
    Loss of the cystine/glutamate antiporter in melanoma abrogates tumor metastasis and dramatically increases survival rates of mice.
    Int J Cancer. 2020 Aug 20. doi: 10.1002/ijc.33262.
    PubMed     Abstract available


  26. ZHAO Y, Amorrortu RP, Fenske NA, Cherpelis B, et al
    Cutaneous viral infections associated with ultraviolet radiation exposure.
    Int J Cancer. 2020 Aug 20. doi: 10.1002/ijc.33263.
    PubMed     Abstract available


  27. MENGONI M, Braun AD, Gaffal E, Tuting T, et al
    The aryl hydrocarbon receptor promotes inflammation-induced dedifferentiation and systemic metastatic spread of melanoma cells.
    Int J Cancer. 2020 Aug 13. doi: 10.1002/ijc.33252.
    PubMed     Abstract available


  28. PAPADIMITRIOU N, Dimou N, Gill D, Tzoulaki I, et al
    Genetically predicted circulating concentrations of micro-nutrients and risk of breast cancer: A Mendelian randomization study.
    Int J Cancer. 2020 Aug 5. doi: 10.1002/ijc.33246.
    PubMed     Abstract available


  29. GAO C, Wang F, Suki D, Strom E, et al
    Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience.
    Int J Cancer. 2020 Aug 4. doi: 10.1002/ijc.33243.
    PubMed     Abstract available


  30. WALPOLE E, Dunn N, Youl P, Harden H, et al
    Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
    Int J Cancer. 2020;147:856-865.
    PubMed     Abstract available


  31. CARIOLI G, Bertuccio P, Malvezzi M, Rodriguez T, et al
    Cancer mortality predictions for 2019 in Latin America.
    Int J Cancer. 2020;147:619-632.
    PubMed     Abstract available


    July 2020
  32. ZHANG J, Yao L, Liu Y, Ouyang T, et al
    Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    Int J Cancer. 2020 Jul 28. doi: 10.1002/ijc.33234.
    PubMed     Abstract available


  33. BARENHOLZ-COHEN T, Merkher Y, Haj J, Shechter D, et al
    Lung mechanics modifications facilitating metastasis are mediated in part by breast cancer derived extracellular vesicles.
    Int J Cancer. 2020 Jul 23. doi: 10.1002/ijc.33229.
    PubMed     Abstract available


  34. YI ZB, Yu P, Zhang S, Wang WN, et al
    Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study.
    Int J Cancer. 2020 Jul 23. doi: 10.1002/ijc.33227.
    PubMed     Abstract available


  35. WANG X, Yu B, Cao B, Zhou J, et al
    A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation.
    Int J Cancer. 2020 Jul 19. doi: 10.1002/ijc.33222.
    PubMed     Abstract available


  36. JABAGI MJ, Vey N, Goncalves A, Le Tri T, et al
    Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: a nationwide population-based cohort.
    Int J Cancer. 2020 Jul 19. doi: 10.1002/ijc.33216.
    PubMed     Abstract available


  37. ZIELONKE N, Kregting LM, Heijnsdijk EAM, Veerus P, et al
    The potential of breast cancer screening in Europe.
    Int J Cancer. 2020 Jul 19. doi: 10.1002/ijc.33204.
    PubMed     Abstract available


  38. FOERSTER M, McKenzie F, Zietsman A, Galukande M, et al
    Dissecting the journey to breast cancer diagnosis in sub-Saharan Africa: Findings from the multi-country ABC-DO cohort study.
    Int J Cancer. 2020 Jul 14. doi: 10.1002/ijc.33209.
    PubMed     Abstract available


  39. AKCAY IM, Celik E, Agaoglu NB, Alkurt G, et al
    Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls.
    Int J Cancer. 2020 Jul 13. doi: 10.1002/ijc.33199.
    PubMed     Abstract available


  40. JUNG AY, Husing A, Behrens S, Krzykalla J, et al
    Postdiagnosis weight change is associated with poorer survival in breast cancer survivors: A prospective population-based patient cohort study.
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33181.
    PubMed     Abstract available


  41. XIE Y, Valdimarsdottir UA, Wang C, Zhong X, et al
    Public health insurance and cancer-specific mortality risk among patients with breast cancer: a prospective cohort study in China.
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33183.
    PubMed     Abstract available


  42. PONTI A, Basu P, Ritchie D, Anttila A, et al
    Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening.
    Int J Cancer. 2020;147:9-13.
    PubMed     Abstract available


    June 2020
  43. CHEN Y, Guan Y, Wang J, Ma F, et al
    Platinum-based chemotherapy in advanced triple-negative breast cancer: a multicenter real-world study in China.
    Int J Cancer. 2020 Jun 25. doi: 10.1002/ijc.33175.
    PubMed     Abstract available


  44. WANG T, Bradshaw PT, Moorman PG, Nyante SJ, et al
    Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island Breast Cancer Study Project.
    Int J Cancer. 2020 Jun 25. doi: 10.1002/ijc.33174.
    PubMed     Abstract available


  45. VAN ZEIJL MCT, Ismail RK, de Wreede LC, van den Eertwegh AJM, et al
    Real-world outcomes of advanced melanoma patients not represented in phase III trials.
    Int J Cancer. 2020 Jun 19. doi: 10.1002/ijc.33162.
    PubMed     Abstract available


  46. TOSS A, Lambertini M, Punie K, Grandi G, et al
    BREAST CANCER SCREENING OF MUTATION CARRIERS IN THE ERA OF COVID-19 PANDEMIC.
    Int J Cancer. 2020 Jun 17. doi: 10.1002/ijc.33160.
    PubMed    


  47. LAN B, Abudureheiyimu N, Zhang J, Wang C, et al
    Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China.
    Int J Cancer. 2020 Jun 14. doi: 10.1002/ijc.33152.
    PubMed     Abstract available


  48. VON DER LIPPE GYTHFELDT H, Lien T, Tekpli X, Silwal-Pandit L, et al
    Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER positive breast cancer.
    Int J Cancer. 2020 Jun 3. doi: 10.1002/ijc.33108.
    PubMed     Abstract available


  49. SANKATSING VDV, van Ravesteyn NT, Heijnsdijk EAM, Broeders MJM, et al
    Risk stratification in breast cancer screening: cost-effectiveness and harm-benefit ratios for low-risk and high-risk women.
    Int J Cancer. 2020 Jun 2. doi: 10.1002/ijc.33126.
    PubMed     Abstract available


  50. XIAO Q, James P, Breheny P, Jia P, et al
    Outdoor light at night and postmenopausal breast cancer risk in the NIH-AARP diet and health study.
    Int J Cancer. 2020 Jun 2. doi: 10.1002/ijc.33016.
    PubMed     Abstract available


    May 2020
  51. RIEDEL F, Hoffmann AS, Moderow M, Heublein S, et al
    Time Trends of Neoadjuvant Chemotherapy for Early Breast Cancer.
    Int J Cancer. 2020 May 28. doi: 10.1002/ijc.33122.
    PubMed     Abstract available


  52. ZONNEVILLE J, Colligan S, Grant S, Miller A, et al
    Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis.
    Int J Cancer. 2020 May 25. doi: 10.1002/ijc.33050.
    PubMed     Abstract available


  53. STANG A, Wellmann I, Kajuter H, Trocchi P, et al
    Differences in site-specific incidence and relative survival of cutaneous and mucocutaneous genital squamous cell carcinoma in Germany, 2007-2015.
    Int J Cancer. 2020 May 23. doi: 10.1002/ijc.33109.
    PubMed     Abstract available


  54. HE Q, Li X, He L, Li Y, et al
    Pericyte dysfunction due to Shb gene deficiency increases B16F10 melanoma lung metastasis.
    Int J Cancer. 2020 May 22. doi: 10.1002/ijc.33110.
    PubMed     Abstract available


  55. SRINIVAS N, Neittaanmaki N, Heidenreich B, Rachakonda S, et al
    TERT promoter mutations in actinic keratosis before and after treatment.
    Int J Cancer. 2020;146:2932-2934.
    PubMed    


  56. HILBERS FS, van 't Hof PJ, Meijers CM, Mei H, et al
    Clustering of known low and moderate risk alleles rather than a novel recessive high-risk gene in non-BRCA1/2 sib trios affected with breast cancer.
    Int J Cancer. 2020 May 7. doi: 10.1002/ijc.33039.
    PubMed     Abstract available


  57. SANDSVEDEN M, Nilsssson E, Borgquist S, Rosendahl AH, et al
    Pre-diagnostic serum selenium levels in relation to breast cancer survival and tumor characteristics.
    Int J Cancer. 2020 May 6. doi: 10.1002/ijc.33031.
    PubMed     Abstract available


  58. CARRERAS G, Lachi A, Boffi R, Clancy L, et al
    Burden of disease from breast cancer attributable to smoking and second-hand smoke exposure in Europe.
    Int J Cancer. 2020 May 1. doi: 10.1002/ijc.33021.
    PubMed     Abstract available


    April 2020
  59. JOKO-FRU WY, Jedy-Agba E, Korir A, Ogunbiyi O, et al
    The evolving epidemic of breast cancer in sub-Saharan Africa. Results from the African Cancer Registry Network.
    Int J Cancer. 2020 Apr 19. doi: 10.1002/ijc.33014.
    PubMed     Abstract available


  60. ZAHL PH, Kalager M, Suhrke P, Nord E, et al
    Quality-of-life effects of screening mammography in Norway.
    Int J Cancer. 2020;146:2104-2112.
    PubMed     Abstract available


  61. ROBINSON SN, Zens MS, Rees JR, Barton DT, et al
    Risk of Melanoma Following Keratinocyte Malignancies.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33011.
    PubMed     Abstract available


  62. ZHENG S, Zou Y, Xie X, Liang JY, et al
    Development and Validation of a Stromal Immune Phenotype Classifier for Predicting Immune Activity and Prognosis in Triple-Negative Breast Cancer.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33009.
    PubMed     Abstract available


  63. TSENG HY, Dreyer J, Al Emran A, Gunatilake D, et al
    Co-targeting BET proteins and MCL1 induces synergistic cell death in melanoma.
    Int J Cancer. 2020 Apr 5. doi: 10.1002/ijc.33000.
    PubMed     Abstract available


    March 2020
  64. KUMAR S, Xie H, Shi H, Gao J, et al
    Merkel cell polyomavirus oncoproteins induce microRNAs that suppress multiple autophagy genes.
    Int J Cancer. 2020;146:1652-1666.
    PubMed     Abstract available


  65. ARMAROLI P, Riggi E, Basu P, Anttila A, et al
    Performance Indicators in Breast Cancer Screening in the European Union: A Comparison Across Countries of Screen Positivity and Detection Rates.
    Int J Cancer. 2020 Mar 11. doi: 10.1002/ijc.32968.
    PubMed     Abstract available


  66. ROBINSON T, Martin RM, Yarmolinsky J
    Mendelian Randomization Analysis of Circulating Adipokines and C-reactive Protein on Breast Cancer Risk.
    Int J Cancer. 2020 Mar 5. doi: 10.1002/ijc.32947.
    PubMed     Abstract available


  67. YIN S, Wang N, Riabov V, Mossel DM, et al
    SI-CLP inhibits the growth of mouse mammary adenocarcinoma by preventing recruitment of tumor-associated macrophages.
    Int J Cancer. 2020;146:1396-1408.
    PubMed     Abstract available


  68. QI L, Zhang Q, Miao Y, Kang W, et al
    Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development.
    Int J Cancer. 2020;146:1421-1434.
    PubMed     Abstract available


    February 2020
  69. FARES J, Kanojia D, Rashidi A, Ulasov I, et al
    Landscape of Combination Therapy Trials in Breast Cancer Brain Metastasis.
    Int J Cancer. 2020 Feb 22. doi: 10.1002/ijc.32937.
    PubMed     Abstract available


  70. FUNCK-BRENTANO E, Baghad B, Fort M, Aouidad I, et al
    Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy.
    Int J Cancer. 2020 Feb 21. doi: 10.1002/ijc.32934.
    PubMed     Abstract available


  71. FIGUEROA JD, Davis Lynn BC, Edusei L, Titiloye N, et al
    Reproductive Factors and Risk of Breast Cancer by Tumor Subtypes among Ghanaian Women: A Population-based Case-control Study.
    Int J Cancer. 2020 Feb 18. doi: 10.1002/ijc.32929.
    PubMed     Abstract available


  72. BAADE PD, Whiteman DC, Janda M, Cust AE, et al
    Long-Term Deaths From Melanoma According To Tumour Thickness At Diagnosis.
    Int J Cancer. 2020 Feb 17. doi: 10.1002/ijc.32930.
    PubMed     Abstract available


  73. ISLAMI F, Sauer AG, Miller KD, Fedewa SA, et al
    Cutaneous melanomas attributable to ultraviolet radiation exposure by state.
    Int J Cancer. 2020 Feb 17. doi: 10.1002/ijc.32921.
    PubMed     Abstract available


  74. PERSSON H, Sokilde R, Hakkinen J, Vallon-Christersson J, et al
    Analysis of fusion transcripts indicates widespread deregulation of snoRNAs and their host genes in breast cancer.
    Int J Cancer. 2020 Feb 17. doi: 10.1002/ijc.32927.
    PubMed     Abstract available


  75. LIU ZH, Chen ML, Zhang Q, Zhang Y, et al
    ZIC2 is downregulated and represses tumor growth via the regulation of STAT3 in breast cancer.
    Int J Cancer. 2020 Feb 16. doi: 10.1002/ijc.32922.
    PubMed     Abstract available


  76. JOHN EM, Phipps AI, Hines LM, Koo J, et al
    Menstrual and reproductive characteristics and breast cancer risk by hormone receptor status and race/ethnicity: The Breast Cancer Etiology in Minorities (BEM) Study.
    Int J Cancer. 2020 Feb 16. doi: 10.1002/ijc.32923.
    PubMed     Abstract available


  77. ZAHL PH, Kalager M
    Reply to: Loss of QALY in mammography screening reported by Zahl et al.
    Int J Cancer. 2020;146:1177.
    PubMed    


  78. NJOR SH, Lynge E
    Loss of QALY in mammography screening reported by Zahl et al.
    Int J Cancer. 2020;146:1176.
    PubMed    


  79. SU L, Xu Y, Ouyang T, Li J, et al
    Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32918.
    PubMed     Abstract available


  80. ZENG, Liang YK, Xiao YS, Wei XL, et al
    Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct down-regulation of MCAM in triple-negative breast cancer cells.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32911.
    PubMed     Abstract available


  81. HENSON KE, McGale P, Darby SC, Parkin DM, et al
    Cardiac Mortality after Radiotherapy, Chemotherapy and Endocrine Therapy for Breast Cancer: Cohort Study of 2 Million Women from 57 Cancer Registries in 22 Countries.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32908.
    PubMed     Abstract available


  82. CHANG VC, Cotterchio M, Bondy SJ, Kotsopoulos J, et al
    Iron intake, oxidative stress-related genes, and breast cancer risk.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32906.
    PubMed     Abstract available


  83. XIAO Q, Zhou Y, Winter S, Buttner F, et al
    Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients.
    Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32898.
    PubMed     Abstract available


  84. SCHOEMAKER MJ, Nichols HB, Wright LB, Brook MN, et al
    Adult weight change and premenopausal breast cancer risk: A prospective pooled analysis of data from 628,463 women.
    Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32892.
    PubMed     Abstract available


    January 2020
  85. MENG H, Yao L, Yuan H, Xu Y, et al
    BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients.
    Int J Cancer. 2020 Jan 20. doi: 10.1002/ijc.32877.
    PubMed     Abstract available


  86. JOHNSTONE CN, Pattison AD, Harrison PF, Powell DR, et al
    FGF13 promotes metastasis of triple-negative breast cancer.
    Int J Cancer. 2020 Jan 19. doi: 10.1002/ijc.32874.
    PubMed     Abstract available


  87. CHOU WC, Hsiung CN, Chen WT, Tseng LM, et al
    A Functional Variant Near XCL1 Gene Improves Breast Cancer Survival via Promoting Cancer Immunity.
    Int J Cancer. 2020 Jan 6. doi: 10.1002/ijc.32855.
    PubMed     Abstract available


  88. ALIPOUR S
    Comments on: Hair dye and chemical straightener use and breast cancer risk in a large US population of black and white women.
    Int J Cancer. 2020 Jan 6. doi: 10.1002/ijc.32852.
    PubMed    


  89. SONNENBLICK A, Salmon-Divon M, Salgado R, Dvash E, et al
    Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer.
    Int J Cancer. 2020 Jan 6. doi: 10.1002/ijc.32859.
    PubMed     Abstract available


  90. VANGANGELT KMH, Green AR, Heemskerk IMF, Cohen D, et al
    The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple negative breast cancer.
    Int J Cancer. 2020 Jan 4. doi: 10.1002/ijc.32857.
    PubMed    


  91. NOME ME, Euceda LR, Jabeen S, Debik J, et al
    Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers.
    Int J Cancer. 2020;146:223-235.
    PubMed     Abstract available


    December 2019
  92. RAINEY L, Eriksson M, Trinh T, Czene K, et al
    The impact of alcohol consumption and physical activity on breast cancer: the role of breast cancer risk.
    Int J Cancer. 2019 Dec 21. doi: 10.1002/ijc.32846.
    PubMed     Abstract available


  93. GUO X, Long J, Chen Z, Shu XO, et al
    Discovery of rare coding variants in OGDHL and BRCA2 in relation to breast cancer risk in Chinese women.
    Int J Cancer. 2019 Dec 13. doi: 10.1002/ijc.32825.
    PubMed     Abstract available


  94. ZHANG D, Nichols HB, Troester M, Cai J, et al
    Tea consumption and breast cancer risk in a cohort of women with family history of breast cancer.
    Int J Cancer. 2019 Dec 13. doi: 10.1002/ijc.32824.
    PubMed     Abstract available


  95. EBERLE CE, Sandler DP, Taylor KW, White AJ, et al
    Hair dye and chemical straightener use and breast cancer risk in a large US population of black and white women.
    Int J Cancer. 2019 Dec 3. doi: 10.1002/ijc.32738.
    PubMed     Abstract available


  96. SALA L, Franco-Valls H, Stanisavljevic J, Curto J, et al
    Abrogation of myofibroblast activities in metastasis and fibrosis by methyltransferase inhibition.
    Int J Cancer. 2019;145:3064-3077.
    PubMed     Abstract available


    November 2019
  97. SUNG H, Devi BCR, Tang TS, Rosenberg PS, et al
    Divergent breast cancer incidence trends by hormone receptor status in the state of Sarawak, Malaysia.
    Int J Cancer. 2019 Nov 28. doi: 10.1002/ijc.32812.
    PubMed     Abstract available


  98. NOH H, Charvat H, Freisling H, Olafsdottir GH, et al
    Cumulative exposure to premenopausal obesity and risk of postmenopausal cancer: A population-based study in Icelandic women.
    Int J Cancer. 2019 Nov 21. doi: 10.1002/ijc.32805.
    PubMed     Abstract available


  99. LIEB WS, Lungu C, Tamas R, Berreth H, et al
    The GEF-H1/PKD3 signaling pathway promotes the maintenance of triple negative breast cancer stem cells.
    Int J Cancer. 2019 Nov 19. doi: 10.1002/ijc.32798.
    PubMed     Abstract available


  100. DE VINCENZO A, Belli S, Franco P, Telesca M, et al
    Paracrine recruitment and activation of fibroblasts by c-Myc expressing breast epithelial cells through the IGFs/IGF-1R axis.
    Int J Cancer. 2019;145:2827-2839.
    PubMed     Abstract available


  101. BASSAN D, Gozlan YM, Sharbi-Yunger A, Tzehoval E, et al
    Optimizing T-cell receptor avidity with somatic hypermutation.
    Int J Cancer. 2019;145:2816-2826.
    PubMed     Abstract available


  102. LAMBERTINI M, Poggio F, Bruzzone M, Conte B, et al
    Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial.
    Int J Cancer. 2019 Nov 13. doi: 10.1002/ijc.32789.
    PubMed     Abstract available


  103. HEEG E, Marang-van de Mheen PJ, Van Maaren MC, Schreuder K, et al
    Association between Initiation of Adjuvant Chemotherapy Beyond 30 Days Following Surgery and Overall Survival Among Patients With Triple-Negative Breast Cancer.
    Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32788.
    PubMed     Abstract available


  104. BELLMANN L, Cappellano G, Schachtl-Riess JF, Prokopi A, et al
    A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
    Int J Cancer. 2019 Nov 8. doi: 10.1002/ijc.32777.
    PubMed     Abstract available


  105. STOTH M, Freire Valls A, Chen M, Hidding S, et al
    Splenectomy reduces lung metastases and tumoral and metastatic niche inflammation.
    Int J Cancer. 2019;145:2509-2520.
    PubMed     Abstract available


  106. KATALINIC A, Eisemann N, Kraywinkel K, Noftz MR, et al
    Breast cancer incidence and mortality before and after implementation of the German mammography screening program.
    Int J Cancer. 2019 Nov 1. doi: 10.1002/ijc.32767.
    PubMed     Abstract available


    October 2019
  107. WU Y, Wang Y, Wang L, Yin P, et al
    Burden of Melanoma in China, 1990-2017: Findings from the 2017 Global Burden of Disease Study.
    Int J Cancer. 2019 Oct 31. doi: 10.1002/ijc.32764.
    PubMed     Abstract available


  108. ZHOU Y, Huang Z, Su J, Li J, et al
    Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment.
    Int J Cancer. 2019 Oct 25. doi: 10.1002/ijc.32756.
    PubMed     Abstract available


  109. BLAZQUEZ R, Rietkotter E, Wenske B, Wlochowitz D, et al
    LEF1 supports metastatic brain colonization by regulating glutathione metabolism and increasing ROS resistance in breast cancer.
    Int J Cancer. 2019 Oct 18. doi: 10.1002/ijc.32742.
    PubMed     Abstract available


  110. NGUYEN TL, Li S, Dite GS, Aung YK, et al
    Interval Breast Cancer Risk Associations with Breast Density, Family History, and Breast Tissue Ageing.
    Int J Cancer. 2019 Oct 14. doi: 10.1002/ijc.32731.
    PubMed     Abstract available


  111. AYENI OA, Norris SA, Joffe M, Cubasch H, et al
    The multimorbidity profile of South African women newly diagnosed with breast cancer.
    Int J Cancer. 2019 Oct 10. doi: 10.1002/ijc.32727.
    PubMed     Abstract available


  112. VAN HEMELRIJCK WMJ, De Schutter H, de Valk HAG, Silversmit G, et al
    Breast cancer by migrant background in Belgium: lower risk, but worse survival in women of non-European origin.
    Int J Cancer. 2019 Oct 9. doi: 10.1002/ijc.32726.
    PubMed     Abstract available


  113. LI X, Wu W, Giovannucci E, Stampfer MJ, et al
    Cutaneous nevi and internal cancer risk: results from two large prospective cohorts of US women.
    Int J Cancer. 2019 Oct 8. doi: 10.1002/ijc.32703.
    PubMed     Abstract available


  114. LUO J, Chen X, Manson JE, Shadyab AH, et al
    Birth weight, weight over the adult life course, and risk of breast cancer.
    Int J Cancer. 2019 Oct 4. doi: 10.1002/ijc.32710.
    PubMed     Abstract available


  115. VAN OPIJNEN MP, Dirven L, Coremans IEM, Taphoorn MJB, et al
    The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: a systematic review.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32696.
    PubMed     Abstract available


  116. CATTERALL R, Lelarge V, McCaffrey L
    Genetic Alterations of Epithelial Polarity Genes are Associated with Loss of Polarity in Invasive Breast Cancer.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32691.
    PubMed     Abstract available


  117. JOHANSSON ALV, Ursin G
    Reply to: "Detection by screening introduces biases into survival estimates for luminal A-like breast cancer patients".
    Int J Cancer. 2019 Oct 1. doi: 10.1002/ijc.32699.
    PubMed    


  118. BUCCHI L, Ravaioli A, Mancini S, Baldacchini F, et al
    Detection by screening introduces biases into survival estimates for luminal A-like breast cancer patients.
    Int J Cancer. 2019 Oct 1. doi: 10.1002/ijc.32697.
    PubMed    


    September 2019
  119. CERVENKA I, Al Rahmoun M, Mahamat-Saleh Y, Fournier A, et al
    Exogenous Hormone Use and Cutaneous Melanoma Risk in Women: The European Prospective Investigation Into Cancer and Nutrition.
    Int J Cancer. 2019 Sep 10. doi: 10.1002/ijc.32674.
    PubMed     Abstract available


  120. KRUGER DT, Alexi X, Opdam M, Schuurman K, et al
    IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
    Int J Cancer. 2019 Sep 6. doi: 10.1002/ijc.32668.
    PubMed     Abstract available


  121. FONTI C, Saumet A, Abi-Khalil A, Orsetti B, et al
    Distinct oncogenes drive different genome and epigenome alterations in human mammary epithelial cells.
    Int J Cancer. 2019;145:1299-1311.
    PubMed     Abstract available


  122. KONG Y, Wang Z, Huang M, Zhou Z, et al
    CUL7 promotes cancer cell survival through promoting Caspase-8 ubiquitination.
    Int J Cancer. 2019;145:1371-1381.
    PubMed     Abstract available


  123. GRUNEWALD S, Politz O, Bender S, Heroult M, et al
    Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
    Int J Cancer. 2019;145:1346-1357.
    PubMed     Abstract available


    August 2019
  124. PRAJZENDANC K, Domagala P, Hybiak J, Rys J, et al
    BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
    Int J Cancer. 2019 Aug 30. doi: 10.1002/ijc.32655.
    PubMed     Abstract available


  125. MANICHAIKUL A, Peres LC, Wang XQ, Barnard ME, et al
    Identification of novel epithelial ovarian cancer loci in Women of African Ancestry.
    Int J Cancer. 2019 Aug 30. doi: 10.1002/ijc.32653.
    PubMed     Abstract available


  126. SILLING S, Soylemez U, Mauch C, Zigrino P, et al
    Human papillomavirus type 197 is not associated with skin tumors.
    Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32646.
    PubMed    


  127. ARROYO MUHR LS, Dillner J
    Reply to: Human papillomavirus type 197 is not associated with skin tumors.
    Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32645.
    PubMed    


  128. BRUSCO I, Li Puma S, Chiepe KB, da Silva Brum E, et al
    Dacarbazine alone or associated with melanoma-bearing cancer pain model induces painful hypersensitivity by TRPA1 activation in mice.
    Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32648.
    PubMed     Abstract available


  129. DEMARK-WAHNEFRIED W, Rogers LQ, Gibson JT, Harada S, et al
    Randomized Trial of Weight Loss in Primary Breast Cancer: Impact on Body Composition, Circulating Biomarkers and Tumor Characteristics.
    Int J Cancer. 2019 Aug 23. doi: 10.1002/ijc.32637.
    PubMed     Abstract available


  130. ELLEBAEK E, Bastholt L, Schmidt H, Svane IM, et al
    The real-world outcome of metastatic melanoma: unknown primary versus known cutaneous.
    Int J Cancer. 2019 Aug 19. doi: 10.1002/ijc.32631.
    PubMed    


  131. VERVER D, van der Veldt A, van Akkooi A, Verhoef C, et al
    Reply to: The real-world outcome of metastatic melanoma: unknown primary versus known cutaneous.
    Int J Cancer. 2019 Aug 19. doi: 10.1002/ijc.32630.
    PubMed    


  132. SCHRAMA D, Sarosi EM, Adam C, Ritter C, et al
    Characterization of six Merkel cell polyomavirus-positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration.
    Int J Cancer. 2019;145:1020-1032.
    PubMed     Abstract available


  133. OUDANONH T, Nabi H, Ennour-Idrissi K, Lemieux J, et al
    Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer.
    Int J Cancer. 2019 Aug 12. doi: 10.1002/ijc.32621.
    PubMed     Abstract available


  134. LO JJ, Park YM, Sinha R, Sandler DP, et al
    Association between meat consumption and risk of breast cancer: Findings from the Sister Study.
    Int J Cancer. 2019 Aug 6. doi: 10.1002/ijc.32547.
    PubMed     Abstract available


  135. FURFARO AL, Ottonello S, Loi G, Cossu I, et al
    HO-1 downregulation favors BRAF(V600) melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition.
    Int J Cancer. 2019 Aug 3. doi: 10.1002/ijc.32611.
    PubMed     Abstract available


    July 2019
  136. MARCINIAK W, Derkacz R, Muszynska M, Baszuk P, et al
    Blood Arsenic Levels and the Risk of Familial Breast Cancer in Poland.
    Int J Cancer. 2019 Jul 26. doi: 10.1002/ijc.32595.
    PubMed     Abstract available


  137. DIETERICH LC, Kapaklikaya K, Cetintas T, Proulx ST, et al
    Transcriptional profiling of breast cancer-associated lymphatic vessels reveals VCAM-1 as regulator of lymphatic invasion and permeability.
    Int J Cancer. 2019 Jul 25. doi: 10.1002/ijc.32594.
    PubMed     Abstract available


  138. CHAN YT, Lai AC, Lin RJ, Wang YH, et al
    GPER-induced signaling is essential for the survival of breast cancer stem cells.
    Int J Cancer. 2019 Jul 24. doi: 10.1002/ijc.32588.
    PubMed     Abstract available


  139. PIZZUTI L, Krasniqi E, Barchiesi G, Della Giulia M, et al
    Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
    Int J Cancer. 2019 Jul 22. doi: 10.1002/ijc.32583.
    PubMed     Abstract available


  140. VAN OURTI T, O'Donnell O, Koc H, Fracheboud J, et al
    Effect of screening mammography on breast-cancer mortality: Quasi-experimental evidence from rollout of the Dutch population-based program with 17-year follow-up of a cohort.
    Int J Cancer. 2019 Jul 22. doi: 10.1002/ijc.32584.
    PubMed     Abstract available


  141. BAI L, Shin S, Burnett RT, Kwong JC, et al
    Exposure to ambient air pollution and the incidence of lung cancer and breast cancer in the Ontario Population Health and Environment Cohort (ONPHEC).
    Int J Cancer. 2019 Jul 15. doi: 10.1002/ijc.32575.
    PubMed     Abstract available


  142. LABO N, Marshall V, Miley W, Davis E, et al
    Mutual detection of Kaposi's sarcoma-associated-Herpesvirus and Epstein Barr virus in blood and saliva of Cameroonians with and without Kaposi's sarcoma.
    Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32546.
    PubMed     Abstract available


  143. SHU X, Bao J, Wu L, Long J, et al
    Evaluation of Associations between Genetically Predicted Circulating Protein Biomarkers and Breast Cancer Risk.
    Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32542.
    PubMed     Abstract available


    June 2019
  144. BRENTNALL AR, van Veen EM, Harkness EF, Rafiq S, et al
    A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density.
    Int J Cancer. 2019 Jun 28. doi: 10.1002/ijc.32541.
    PubMed     Abstract available


  145. MA F, Guan Y, Yi Z, Chang L, et al
    Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer.
    Int J Cancer. 2019 Jun 26. doi: 10.1002/ijc.32536.
    PubMed     Abstract available


  146. PERSON H, Guillemin F, Conroy T, Velten M, et al
    Factors of the evolution of fatigue dimensions in patients with breast cancer during the 2 years after surgery.
    Int J Cancer. 2019 Jun 22. doi: 10.1002/ijc.32527.
    PubMed     Abstract available


  147. GENG N, Li Y, Zhang W, Wang F, et al
    A PAK5-DNPEP-USP4 axis dictates breast cancer growth and metastasis.
    Int J Cancer. 2019 Jun 20. doi: 10.1002/ijc.32523.
    PubMed     Abstract available


  148. GENER LAHAV T, Adler O, Zait Y, Shani O, et al
    Melanoma-derived extracellular vesicles instigate pro-inflammatory signaling in the metastatic microenvironment.
    Int J Cancer. 2019 Jun 19. doi: 10.1002/ijc.32521.
    PubMed     Abstract available


  149. SINGH D, Malila N, Pitkaniemi J, Anttila A, et al
    Cancer incidence and mortality patterns in women with breast symptoms in the mammography screening programme: A matched cohort analysis.
    Int J Cancer. 2019;144:2928-2935.
    PubMed     Abstract available


  150. KINOSHITA R, Sato H, Yamauchi A, Takahashi Y, et al
    exSSSRs (extracellular S100 soil sensor receptors)-Fc fusion proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis.
    Int J Cancer. 2019;144:3138-3145.
    PubMed     Abstract available


  151. DASHTI SG, Simpson JA, Karahalios A, Viallon V, et al
    Adiposity and estrogen receptor-positive, postmenopausal breast cancer risk: quantification of the mediating effects of fasting insulin and free estradiol.
    Int J Cancer. 2019 Jun 12. doi: 10.1002/ijc.32504.
    PubMed     Abstract available


  152. CYBULSKI C, Kluzniak W, Huzarski T, Wokolorczyk D, et al
    The Spectrum of Mutations Predisposing to Familial Breast Cancer in Poland.
    Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32492.
    PubMed     Abstract available


  153. WANG S, Pitt JJ, Zheng Y, Yoshimatsu TF, et al
    Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria.
    Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32498.
    PubMed     Abstract available


  154. AN KY, Morielli AR, Kang DW, Friedenreich CM, et al
    Effects of exercise dose and type during breast cancer chemotherapy on longer-term patient-reported outcomes and health-related fitness: A randomized controlled trial.
    Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32493.
    PubMed     Abstract available


  155. GLUZ O, Kolberg-Liedtke C, Prat A, Christgen M, et al
    Efficacy of de-escalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
    Int J Cancer. 2019 Jun 4. doi: 10.1002/ijc.32488.
    PubMed     Abstract available


    May 2019
  156. OROUJI E, Federico A, Larribere L, Novak D, et al
    Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.
    Int J Cancer. 2019 May 27. doi: 10.1002/ijc.32432.
    PubMed     Abstract available


  157. GAO X, Wilsgaard T, Jansen EH, Xuan Y, et al
    Serum total thiol levels and the risk of lung, colorectal, breast and prostate cancer: A prospective case-cohort study.
    Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32428.
    PubMed     Abstract available


  158. LI G, Xie Q, Yang Z, Wang L, et al
    Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
    Int J Cancer. 2019 May 21. doi: 10.1002/ijc.32425.
    PubMed     Abstract available


  159. SHENG S, Xu Y, Guo Y, Yao L, et al
    Prevalence and Clinical Impact of TP53 Germline Mutations in Chinese Women with Breast Cancer.
    Int J Cancer. 2019 May 21. doi: 10.1002/ijc.32424.
    PubMed     Abstract available


  160. TRAPANI D, Rajasekar AKA, Mathew A
    More options for adjuvant treatment of HER2-positive breast cancer: How to choose wisely?
    Int J Cancer. 2019 May 20. doi: 10.1002/ijc.32418.
    PubMed     Abstract available


  161. JACOT W, Heudel PE, Fraisse J, Gourgou S, et al
    Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
    Int J Cancer. 2019 May 14. doi: 10.1002/ijc.32402.
    PubMed     Abstract available


  162. KLEIBLOVA P, Stolarova L, Krizova K, Lhota F, et al
    Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32385.
    PubMed     Abstract available


  163. BAO C, Yang R, Pedersen NL, Xu W, et al
    Overweight in midlife and risk of cancer in late life: A nationwide Swedish twin study.
    Int J Cancer. 2019;144:2128-2134.
    PubMed     Abstract available


  164. WU J, Crowe DL
    Molecular and cellular basis of mammary gland fibrosis and cancer risk.
    Int J Cancer. 2019;144:2239-2253.
    PubMed     Abstract available


    April 2019
  165. GE J, Liu H, Qian D, Wang X, et al
    Genetic variants of genes in the NER pathway associated with risk of breast cancer: a large-scale analysis of 14 published GWAS datasets in the DRIVE Study.
    Int J Cancer. 2019 Apr 26. doi: 10.1002/ijc.32371.
    PubMed     Abstract available


  166. FEKETE JT, Gyorffy B
    ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients.
    Int J Cancer. 2019 Apr 24. doi: 10.1002/ijc.32369.
    PubMed     Abstract available


  167. YEO HL, Fan TC, Lin RJ, Yu JC, et al
    Sialylation of vasorin by ST3Gal1 facilitates TGF-beta1-mediated tumor angiogenesis and progression.
    Int J Cancer. 2019;144:1996-2007.
    PubMed     Abstract available


  168. LIU LC, Wang YL, Lin PL, Zhang X, et al
    Long non-coding RNA HOTAIR promotes invasion of breast cancer cells through chondroitin sulfotransferase CHST15.
    Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32319.
    PubMed     Abstract available


  169. ZUR HAUSEN H, Bund T, de Villiers EM
    Specific nutritional infections early in life as risk factors for human colon and breast cancers several decades later.
    Int J Cancer. 2019;144:1574-1583.
    PubMed    


    March 2019
  170. VARGA Z, Sinn P, Seidman AD
    Comparing the performance of gene expression assays in breast cancer.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32289.
    PubMed    


  171. SUTHERS GK
    Comparing the performance of gene expression assays in breast cancer.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32290.
    PubMed    


  172. KIM EY, Chang Y, Lee KH, Yun JS, et al
    Serum concentration of thyroid hormones in abnormal and euthyroid ranges and breast cancer risk: A cohort study.
    Int J Cancer. 2019 Mar 18. doi: 10.1002/ijc.32283.
    PubMed     Abstract available


  173. COUSSY F, de Koning L, Lavigne M, Bernard V, et al
    A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
    Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32266.
    PubMed     Abstract available


  174. GIULIANELLI S, Riggio M, Guillardoy T, Perez Pinero C, et al
    FGF2 Induces Breast Cancer Growth through Ligand-Independent Activation and Recruitment of ERalpha and PRB4 Isoform to MYC Regulatory Sequences.
    Int J Cancer. 2019 Mar 7. doi: 10.1002/ijc.32252.
    PubMed     Abstract available


    February 2019
  175. ARRIAGA ME, Vajdic CM, Canfell K, MacInnis RJ, et al
    The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: a pooled cohort study.
    Int J Cancer. 2019 Feb 25. doi: 10.1002/ijc.32231.
    PubMed     Abstract available


  176. VERVER D, van der Veldt A, van Akkooi A, Verhoef C, et al
    Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: a Dutch population-based study.
    Int J Cancer. 2019 Feb 23. doi: 10.1002/ijc.32229.
    PubMed     Abstract available


  177. MIO C, Gerratana L, Bolis M, Caponnetto F, et al
    BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Int J Cancer. 2019;144:755-766.
    PubMed     Abstract available


  178. KIENY A, Cribier B, Meyer N, Velten M, et al
    Epidemiology of Merkel cell carcinoma. A population-based study from 1985 to 2013, in northeastern of France.
    Int J Cancer. 2019;144:741-745.
    PubMed     Abstract available


  179. ALTANEROVA U, Jakubechova J, Benejova K, Priscakova P, et al
    Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes.
    Int J Cancer. 2019;144:897-908.
    PubMed     Abstract available


  180. MANDRIK O, Zielonke N, Meheus F, Severens JLH, et al
    Systematic reviews as a "lens of evidence": determinants of benefits and harms of breast cancer screening.
    Int J Cancer. 2019 Feb 14. doi: 10.1002/ijc.32211.
    PubMed     Abstract available


  181. DE KRUIJFF IE, Sieuwerts AM, Onstenk W, Jager A, et al
    Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer.
    Int J Cancer. 2019 Feb 13. doi: 10.1002/ijc.32209.
    PubMed     Abstract available


  182. VAN HELLEMOND IEG, Smorenburg CH, Peer PGM, Swinkels ACP, et al
    Assessment and Management of Bone Health in Women with Early Breast Cancer Receiving Endocrine Treatment in the DATA Study.
    Int J Cancer. 2019 Feb 12. doi: 10.1002/ijc.32205.
    PubMed     Abstract available


  183. DAI W, Liu H, Xu X, Jie G, et al
    Genetic variants in ELOVL2 and HSD17B12 predict melanoma-specific survival.
    Int J Cancer. 2019 Feb 8. doi: 10.1002/ijc.32194.
    PubMed     Abstract available


  184. ZEINOMAR N, Phillips KA, Daly MB, Milne RL, et al
    Benign Breast Disease Increases Breast Cancer Risk Independent of Underlying Familial Risk Profile: Findings from a Prospective Family Study Cohort (ProF-SC).
    Int J Cancer. 2019 Feb 6. doi: 10.1002/ijc.32112.
    PubMed     Abstract available


  185. SUN W, Xu X, Jiang Y, Jin X, et al
    Transcriptome analysis of Luminal Breast Cancer Reveals a Role for LOL in Tumor Progression and Tamoxifen Resistance.
    Int J Cancer. 2019 Feb 5. doi: 10.1002/ijc.32185.
    PubMed     Abstract available


    January 2019
  186. BHASKARAN SP, Chandratre K, Gupta H, Zhang L, et al
    Germline variation in BRCA1/2 is highly ethnic-specific: evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.
    Int J Cancer. 2019 Jan 31. doi: 10.1002/ijc.32176.
    PubMed     Abstract available


  187. FRANKE V, Berger DMS, Klop WMC, van der Hiel B, et al
    High Response Rates for T-VEC in Early Metastatic Melanoma (Stage IIIB/C-IVM1a).
    Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32172.
    PubMed     Abstract available


  188. CERVENKA I, Al Rahmoun M, Mahamat Saleh Y, Savoye I, et al
    Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study.
    Int J Cancer. 2019 Jan 22. doi: 10.1002/ijc.32150.
    PubMed     Abstract available


  189. CADENAS C, Vosbeck S, Edlund K, Grgas K, et al
    LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancer.
    Int J Cancer. 2019 Jan 17. doi: 10.1002/ijc.32138.
    PubMed     Abstract available


  190. VARGA Z, Sinn P, Seidman AD
    Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score(R) (RS) assay and other genomic assays for early breast cancer.
    Int J Cancer. 2019 Jan 17. doi: 10.1002/ijc.32139.
    PubMed     Abstract available


  191. BRANDAO RD, Mensaert K, Lopez-Perolio I, Tserpelis D, et al
    Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
    Int J Cancer. 2019 Jan 8. doi: 10.1002/ijc.32114.
    PubMed     Abstract available


  192. RIZZOLO P, Zelli V, Silvestri V, Valentini V, et al
    Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.
    Int J Cancer. 2019 Jan 7. doi: 10.1002/ijc.32106.
    PubMed     Abstract available


  193. CAHOON EK, Engels EA
    "Decreased incidence of Kaposi sarcoma after kidney transplant in Italy and role of mTOR-inhibitors: 1997-2016" Reply to Letter re: Risk of Kaposi sarcoma after solid organ transplantation in the United States.
    Int J Cancer. 2019 Jan 6. doi: 10.1002/ijc.32096.
    PubMed    


  194. PISELLI P, Taborelli M, Cimaglia C, Serraino D, et al
    Decreased incidence of Kaposi sarcoma after kidney transplant in Italy and role of mTOR-inhibitors: 1997-2016.
    Int J Cancer. 2019 Jan 6. doi: 10.1002/ijc.32098.
    PubMed    


    December 2018
  195. WEIDELE K, Stojanovic N, Feliciello G, Markiewicz A, et al
    Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samples.
    Int J Cancer. 2018 Dec 26. doi: 10.1002/ijc.32092.
    PubMed     Abstract available


  196. VAN HELLEMOND IEG, Vriens IJH, Peer PGM, Swinkels ACP, et al
    Efficacy of Anastrozole after Tamoxifen in Early Breast Cancer Patients with Chemotherapy-Induced Ovarian Function Failure.
    Int J Cancer. 2018 Dec 26. doi: 10.1002/ijc.32093.
    PubMed     Abstract available


  197. SUNG H, Guo C, Li E, Li J, et al
    The relationship between terminal duct lobular unit features and mammographic density among Chinese breast cancer patients.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32077.
    PubMed     Abstract available


  198. GUO D, Lui GYL, Lai SL, Wilmott JS, et al
    RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes.
    Int J Cancer. 2018 Dec 17. doi: 10.1002/ijc.32064.
    PubMed     Abstract available


  199. POLLOM EL, Qian Y, Chin AL, Dirbas FM, et al
    Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy.
    Int J Cancer. 2018;143:3262-3272.
    PubMed     Abstract available


  200. HAMERS FF, Assogba FAG, Rogel A
    Implementation and organization of cancer screening in France.
    Int J Cancer. 2018;143:3281.
    PubMed    


  201. GRIONI S, Agnoli C, Krogh V, Pala V, et al
    Dietary cadmium and risk of breast cancer subtypes defined by hormone receptor status: a prospective cohort study.
    Int J Cancer. 2018 Dec 4. doi: 10.1002/ijc.32039.
    PubMed     Abstract available


  202. GRAF ME, Sookthai D, Johnson T, Schubel R, et al
    Pre-diagnostic plasma concentrations of Fibrinogen, sGPIIb/IIIa, sP-selectin, sThrombomodulin, Thrombopoietin in relation to cancer risk: Findings from a large prospective study.
    Int J Cancer. 2018;143:2659-2667.
    PubMed     Abstract available


  203. MIGLIO U, Berrino E, Panero M, Ferrero G, et al
    The expression of LINE1-MET chimeric transcript identifies a subgroup of aggressive breast cancers.
    Int J Cancer. 2018;143:2838-2848.
    PubMed     Abstract available


    November 2018
  204. TORRES D, Lorenzo Bermejo J, Garcia Mesa K, Gilbert M, et al
    Interaction between genetic ancestry and common breast cancer susceptibility variants in Colombian women.
    Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32023.
    PubMed     Abstract available


  205. KLASCHIK K, Hauke J, Neidhardt G, Trankle C, et al
    The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
    Int J Cancer. 2018 Nov 26. doi: 10.1002/ijc.32016.
    PubMed    


  206. BULANOVA DR, Helenius M, Sokolenko AP, Kuznetsov SG, et al
    Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
    Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32013.
    PubMed    


  207. PEREIRA-VEIGA T, Abreu M, Robledo D, Matias-Guiu X, et al
    CTCs-derived xenograft development in a Triple Negative breast cancer case.
    Int J Cancer. 2018 Nov 19. doi: 10.1002/ijc.32001.
    PubMed     Abstract available


  208. RUEEGG CS, Stenehjem JS, Egger M, Ghiasvand R, et al
    Challenges in Assessing the Sunscreen-Melanoma Association.
    Int J Cancer. 2018 Nov 16. doi: 10.1002/ijc.31997.
    PubMed     Abstract available


  209. SROUR B, Plancoulaine S, Andreeva VA, Fassier P, et al
    Circadian nutritional behaviours and cancer risk: New insights from the NutriNet-sante prospective cohort study: Disclaimers.
    Int J Cancer. 2018;143:2369-2379.
    PubMed     Abstract available


  210. SCHUBERT S, van Luttikhuizen JL, Auber B, Schmidt G, et al
    The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: high frequency of FANCM pathogenic variants.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31992.
    PubMed     Abstract available


  211. YUAN B, Schafferer S, Tang Q, Scheffler M, et al
    A plasma metabolite panel as biomarkers for early primary breast cancer detection.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31996.
    PubMed     Abstract available


  212. POTJER TP, Bollen S, Grimbergen AJEM, van Doorn R, et al
    Multi-gene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
    Int J Cancer. 2018 Nov 10. doi: 10.1002/ijc.31984.
    PubMed     Abstract available


  213. ASLEH K, Lyck Carstensen S, Tykjaer Jorgensen CL, Burugu S, et al
    Basal biomarkers Nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: samples from the phase III SBG0102 clinical trial.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31969.
    PubMed     Abstract available


  214. MINICOZZI P, Van Eycken L, Molinie F, Innos K, et al
    Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer.
    Int J Cancer. 2018 Nov 8. doi: 10.1002/ijc.31974.
    PubMed     Abstract available


    October 2018
  215. VAN MAAREN MC, de Munck L, Strobbe LJ, Sonke GS, et al
    10-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study.
    Int J Cancer. 2018 Oct 28. doi: 10.1002/ijc.31914.
    PubMed     Abstract available


  216. SUN L, Sadique Z, Dos-Santos-Silva I, Yang L, et al
    Cost-effectiveness of Breast Cancer Screening Programme for Women in Rural China.
    Int J Cancer. 2018 Oct 27. doi: 10.1002/ijc.31956.
    PubMed     Abstract available


  217. JOHANSSON ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, et al
    Breast cancer-specific survival by clinical subtype after seven years follow-up of young and elderly women in a nationwide cohort.
    Int J Cancer. 2018 Oct 26. doi: 10.1002/ijc.31950.
    PubMed     Abstract available


  218. BENS A, Cronin-Fenton D, Dehlendorff C, Jensen MB, et al
    Non-aspirin NSAIDs and contralateral breast cancer risk.
    Int J Cancer. 2018 Oct 26. doi: 10.1002/ijc.31949.
    PubMed    


  219. HOUGHTON SC, Eliassen AH, Zhang SM, Selhub J, et al
    Plasma B-vitamin and one-carbon metabolites and risk of breast cancer before and after folic acid fortification in the US.
    Int J Cancer. 2018 Oct 22. doi: 10.1002/ijc.31934.
    PubMed     Abstract available


  220. GIRARD E, Eon-Marchais S, Olaso R, Renault AL, et al
    Familial breast cancer and DNA repair genes: insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
    Int J Cancer. 2018 Oct 10. doi: 10.1002/ijc.31921.
    PubMed     Abstract available


  221. BERRANDOU T, Mulot C, Cordina-Duverger E, Arveux P, et al
    Association of breast cancer risk with polymorphisms in genes involved in the metabolism of xenobiotics and interaction with tobacco smoking: a gene-set analysis.
    Int J Cancer. 2018 Oct 10. doi: 10.1002/ijc.31917.
    PubMed     Abstract available


  222. SHEN Y, Zhang W, Liu J, He J, et al
    Therapeutic Activity of DCC-2036, a Novel Tyrosine Kinase Inhibitor, against Triple-Negative Breast Cancer Patient-Derived Xenografts by Targeting AXL/MET.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31915.
    PubMed     Abstract available


  223. LATTOUF H, Kassem L, Jacquemetton J, Choucair A, et al
    LKB1 regulates PRMT5 activity in breast cancer.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31909.
    PubMed     Abstract available


    September 2018
  224. HARDING C, Pompei F, Burmistrov D, Wilson R, et al
    Long-term relationships between screening rates, breast cancer characteristics, and overdiagnosis in US counties, 1975-2009.
    Int J Cancer. 2018 Sep 28. doi: 10.1002/ijc.31904.
    PubMed     Abstract available


  225. JI J, Sundquist J, Sundquist K
    Use of terbinafine and risk of death in patients with prostate cancer: A population-based cohort study.
    Int J Cancer. 2018 Sep 27. doi: 10.1002/ijc.31901.
    PubMed     Abstract available


  226. ELANDS RJ, Offermans NS, Simons CC, Schouten LJ, et al
    Associations of adult-attained height and early life energy restriction with postmenopausal breast cancer risk according to estrogen and progesterone receptor status.
    Int J Cancer. 2018 Sep 25. doi: 10.1002/ijc.31890.
    PubMed     Abstract available


  227. PARK YM, Steck SE, Fung TT, Merchant AT, et al
    Higher diet-dependent acid load is associated with risk of breast cancer: Findings from the Sister Study.
    Int J Cancer. 2018 Sep 24. doi: 10.1002/ijc.31889.
    PubMed     Abstract available


  228. DASSLER-PLENKER J, Paschen A, Putschli B, Rattay S, et al
    Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity towards autologous melanoma cells.
    Int J Cancer. 2018 Sep 19. doi: 10.1002/ijc.31874.
    PubMed     Abstract available


  229. STROHSNITTER WC, Bertrand KA, Troisi R, Scott CG, et al
    Prenatal diethylstilbestrol exposure and mammographic density.
    Int J Cancer. 2018;143:1374-1378.
    PubMed     Abstract available


  230. LIN MC, Chen SY, He PL, Herschman H, et al
    PGE2 /EP4 antagonism enhances tumor chemosensitivity by inducing extracellular vesicle-mediated clearance of cancer stem cells.
    Int J Cancer. 2018;143:1440-1455.
    PubMed     Abstract available


  231. EL-MALLAWANY NK, Mehta PS, Kamiyango W, Villiera J, et al
    KSHV Viral Load and Interleukin-6 in HIV-Associated Pediatric Kaposi Sarcoma-Exploring the Role of Lytic Activation in Driving the Unique Clinical Features Seen in Endemic Regions.
    Int J Cancer. 2018 Sep 11. doi: 10.1002/ijc.31863.
    PubMed     Abstract available


  232. HAM SA, Kim E, Yoo T, Lee WJ, et al
    Ligand-activated interaction of PPARdelta with c-Myc governs the tumorigenicity of breast cancer.
    Int J Cancer. 2018 Sep 11. doi: 10.1002/ijc.31864.
    PubMed     Abstract available


  233. KOMEMI O, Epstein Shochet G, Pomeranz M, Fishman A, et al
    Placenta-conditioned extracellular matrix (ECM) activates breast cancer cell survival mechanisms: A key for future distant metastases.
    Int J Cancer. 2018 Sep 8. doi: 10.1002/ijc.31861.
    PubMed     Abstract available


  234. BRADBURY KE, Appleby PN, Tipper SJ, Travis RC, et al
    Circulating insulin-like growth factor I in relation to melanoma risk in the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31854.
    PubMed     Abstract available


  235. JIN ML, Kim YW, Jin HL, Kang H, et al
    Aberrant expression of SETD1A promotes survival and migration of estrogen receptor alpha-positive breast cancer cells.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31853.
    PubMed     Abstract available


  236. FARVID MS, Stern MC, Norat T, Sasazuki S, et al
    Consumption of red and processed meat and breast cancer incidence: a systematic review and meta-analysis of prospective studies.
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31848.
    PubMed     Abstract available


  237. FALK RT, Manson JE, Barnabei VM, Anderson GL, et al
    Estrogen metabolism in menopausal hormone users in the Women's Health Initiative Observational Study: Does it differ between estrogen plus progestin and estrogen alone?
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31851.
    PubMed     Abstract available


  238. WILMOTT JS, Johansson PA, Newell F, Waddell N, et al
    Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility.
    Int J Cancer. 2018 Sep 4. doi: 10.1002/ijc.31791.
    PubMed     Abstract available


  239. LI J, Wen WX, Eklund M, Kvist A, et al
    Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
    Int J Cancer. 2018 Sep 2. doi: 10.1002/ijc.31841.
    PubMed     Abstract available


    August 2018
  240. YE L, Li F, Song Y, Yu D, et al
    Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of Triple-Negative Breast Cancer.
    Int J Cancer. 2018 Aug 27. doi: 10.1002/ijc.31766.
    PubMed     Abstract available


  241. MOLLER MH, Lousdal ML, Kristiansen IS, Stovring H, et al
    Effect of organised mammography screening on breast cancer mortality: A population-based cohort study in Norway.
    Int J Cancer. 2018 Aug 25. doi: 10.1002/ijc.31832.
    PubMed     Abstract available


  242. ZHAO B, Zhao H, Zhao J
    Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma.
    Int J Cancer. 2018 Aug 19. doi: 10.1002/ijc.31813.
    PubMed     Abstract available


  243. GAUDET MM, Deubler EL, Kelly RS, Diver WR, et al
    Blood Levels of Cadmium and Lead in Relation to Breast Cancer Risk in Three Prospective Cohorts.
    Int J Cancer. 2018 Aug 17. doi: 10.1002/ijc.31805.
    PubMed     Abstract available


  244. WU H, Larribere L, Sun Q, Novak D, et al
    Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation.
    Int J Cancer. 2018 Aug 15. doi: 10.1002/ijc.31799.
    PubMed     Abstract available


  245. MC MENAMIN UC, Kunzmann AT, Cook MB, Johnston BT, et al
    Hormonal and reproductive factors and risk of upper gastrointestinal cancers in men: A prospective cohort study within the UK Biobank.
    Int J Cancer. 2018;143:831-841.
    PubMed     Abstract available


  246. KIVES Z, Juhasz K, Csakvari T, Agoston I, et al
    Cancer screening policy in Hungary.
    Int J Cancer. 2018;143:1003-1004.
    PubMed    


  247. PEDERSEN MH, Hood BL, Ehmsen S, Beck HC, et al
    CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
    Int J Cancer. 2018 Aug 15. doi: 10.1002/ijc.31798.
    PubMed     Abstract available


  248. SHARBI-YUNGER A, Grees M, Gal C, Bassan D, et al
    A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Int J Cancer. 2018 Aug 14. doi: 10.1002/ijc.31795.
    PubMed     Abstract available


  249. LEE WH, Chen LC, Lee CJ, Huang CC, et al
    DNA primase polypeptide 1 (PRIM1) involves in estrogen-induced breast cancer formation through activation of the G2/M cell cycle checkpoint.
    Int J Cancer. 2018 Aug 11. doi: 10.1002/ijc.31788.
    PubMed     Abstract available


  250. CORTESI L, Canossi B, Battista R, Pecchi A, et al
    Breast ultrasonography in the screening protocol for women at hereditary- familial risk of breast cancer: Has the time come to rethink the role of BU according to different risk categories?
    Int J Cancer. 2018 Aug 11. doi: 10.1002/ijc.31794.
    PubMed     Abstract available


  251. ANDRES-LENCINA JJ, Rachakonda S, Garcia-Casado Z, Srinivas N, et al
    TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31780.
    PubMed     Abstract available


  252. CHUANG SC, Lin CH, Lu YS, Hsiung CA, et al
    Association of pregnancy and mortality in women diagnosed with breast cancer: A nationwide population based study in Taiwan.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31777.
    PubMed     Abstract available


  253. KWOK ZH, Roche V, Chew XH, Fadieieva A, et al
    A non-canonical tumor suppressive role for the long non-coding RNA MALAT1 in colon and breast cancers.
    Int J Cancer. 2018;143:668-678.
    PubMed     Abstract available


  254. OH H, Pfeiffer RM, Falk RT, Horne HN, et al
    Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank.
    Int J Cancer. 2018;143:496-507.
    PubMed     Abstract available


    July 2018
  255. KOGEVINAS M, Espinosa A, Castello A, Gomez-Acebo I, et al
    Effect of mistimed eating patterns on breast and prostate cancer risk (MCC-Spain Study).
    Int J Cancer. 2018 Jul 17. doi: 10.1002/ijc.31649.
    PubMed     Abstract available


  256. ANDREE KC, Mentink A, Zeune LL, Terstappen LWMM, et al
    Towards a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multi-center study (CTCTrap).
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31752.
    PubMed     Abstract available


  257. BASU P, Selmouni F, Belakhel L, Sauvaget C, et al
    Breast Cancer Screening Program in Morocco: Status of implementation, organization and performance.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31749.
    PubMed     Abstract available


  258. IZRAELY S, Ben-Menachem S, Sagi-Assif O, Telerman A, et al
    The Metastatic Microenvironment: Melanoma-Microglia Cross-Talk Promotes the Malignant Phenotype of Melanoma Cells.
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31745.
    PubMed     Abstract available


  259. MCCORMACK V, Febvey-Combes O, Ginsburg O, Dos-Santos-Silva I, et al
    Breast cancer in women living with HIV: A first global estimate.
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31722.
    PubMed     Abstract available


  260. CLENDENEN TV, Dorgan J, Zeleniuch-Jacquotte A
    Reply to: Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31728.
    PubMed    


  261. TESCH H, Stoetzer O, Decker T, Kurbacher CM, et al
    Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31738.
    PubMed     Abstract available


  262. CAHOON EK, Linet MS, Clarke CA, Pawlish KS, et al
    Risk of Kaposi sarcoma after solid organ transplantation in the United States.
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31735.
    PubMed     Abstract available


  263. STERNBERG C, Gruber W, Eberl M, Tesanovic S, et al
    Synergistic Cross-Talk of Hedgehog and Interleukin-6 Signaling Drives Growth of Basal Cell Carcinoma.
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31724.
    PubMed     Abstract available


  264. BLUMENFELD Z
    Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31732.
    PubMed    


  265. YANG CC, Chang CK, Chang MT, Shyur LF, et al
    Plant galactolipid dLGG suppresses lung metastasis of melanoma through deregulating TNF-alpha-mediated pulmonary vascular permeability and circulating oxylipin dynamics in mice.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31663.
    PubMed     Abstract available


  266. CERVENKA I, Mahamat-Saleh Y, Savoye I, Dartois L, et al
    Oral contraceptive use and cutaneous melanoma risk: A french prospective cohort study.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31644.
    PubMed     Abstract available


  267. LAN B, Ma F, Chen S, Wang W, et al
    Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10 T/T genotype breast cancer patients in China.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31639.
    PubMed     Abstract available


  268. PARK YH, Lee KH, Sohn JH, Lee KS, et al
    A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31651.
    PubMed     Abstract available


  269. VANGANGELT KMH, Tollenaar LSA, van Pelt GW, de Kruijf EM, et al
    The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31658.
    PubMed     Abstract available


  270. SALEM Y, Yacov N, Propheta-Meiran O, Breitbart E, et al
    Newly Characterized Motile Sperm Domain-Containing Protein 2 Promotes Human Breast Cancer Metastasis.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31665.
    PubMed     Abstract available


  271. JASKULSKI S, Jung AY, Behrens S, Johnson T, et al
    Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: Assessment of mediation by inflammatory markers.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31647.
    PubMed     Abstract available


  272. KISO M, Tanaka S, Saji S, Toi M, et al
    Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31645.
    PubMed     Abstract available


  273. TAN J, Fu L, Chen H, Guan J, et al
    Association study of genetic variation in the autophagy lysosome pathway genes and risk of eight kinds of cancers.
    Int J Cancer. 2018;143:80-87.
    PubMed     Abstract available


    June 2018
  274. HUSER L, Sachindra, Granados K, Federico A, et al
    SOX2-mediated upregulation of CD24 promotes adaptive resistance towards targeted therapy in melanoma.
    Int J Cancer. 2018 Jun 15. doi: 10.1002/ijc.31609.
    PubMed     Abstract available


    May 2018
  275. WU W, Chen F, Cui X, Yang L, et al
    LncRNA NKILA Suppresses TGF-beta-induced Epithelial-Mesenchymal Transition by Blocking NF-kappaB Signaling in Breast Cancer.
    Int J Cancer. 2018 May 15. doi: 10.1002/ijc.31605.
    PubMed     Abstract available


  276. LA MANNA S, Lee E, Ouzounova M, Di Natale C, et al
    Mimetics of Suppressor of cytokine signalling 3: novel potential therapeutics in triple breast cancer.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31594.
    PubMed     Abstract available


  277. XIE J, Shen K, Lenchine RV, Gethings LA, et al
    Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis.
    Int J Cancer. 2018;142:1865-1877.
    PubMed     Abstract available


    April 2018
  278. LI J, Wang W, Xia P, Wan L, et al
    Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in breast cancer patients.
    Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31573.
    PubMed     Abstract available


  279. AL-AWADHI A, Murray JL, Ibrahim NK
    Developing Anti-HER2 Vaccines: Breast Cancer Experience.
    Int J Cancer. 2018 Apr 25. doi: 10.1002/ijc.31551.
    PubMed     Abstract available


  280. ARNOLD M, de Vries E, Whiteman DC, Jemal A, et al
    Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31527.
    PubMed     Abstract available


  281. WILKE CM, Braselmann H, Hess J, Klymenko SV, et al
    A genomic copy number signature predicts radiation exposure in post-Chernobyl breast cancer.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31533.
    PubMed     Abstract available


  282. BOCK J, Appenzeller S, Haertle L, Schneider T, et al
    Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31526.
    PubMed     Abstract available


  283. SHAFIEE A, McGovern JA, Lahr CA, Meinert C, et al
    Immune System Augmentation via Humanization Using Stem/Progenitor Cells and Bioengineering in a Breast Cancer Model Study.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31528.
    PubMed     Abstract available


  284. CAO C, Wu H, Vasilatos SN, Chandran U, et al
    HDAC5-LSD1 Axis Regulates Antineoplastic Effect of Natural HDAC Inhibitor Sulforaphane in Human Breast Cancer Cells.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31419.
    PubMed     Abstract available


  285. NJOR SH, Paci E, Rebolj M
    As you like it: How the same data can support manifold views of overdiagnosis in breast cancer screening.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31420.
    PubMed     Abstract available


    March 2018
  286. ERIKSSON L, Bergh J, Humphreys K, Warnberg F, et al
    Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study.
    Int J Cancer. 2018 Mar 31. doi: 10.1002/ijc.31411.
    PubMed     Abstract available


  287. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
    A dietary pattern based on estrogen metabolism is associated with breast cancer risk in a prospective cohort of postmenopausal women.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31387.
    PubMed     Abstract available


  288. DE MUNCK L, Fracheboud J, de Bock GH, den Heeten GJ, et al
    Is the incidence of advanced-stage breast cancer affected by whether women attend a steady-state screening program?
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31388.
    PubMed     Abstract available


  289. GUO W, Key TJ, Reeves GK
    Adiposity and breast cancer risk in postmenopausal women: Results from the UK Biobank prospective cohort.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31394.
    PubMed     Abstract available


  290. WEI F, Li M, Wu X, Yin K, et al
    The prevalence and concordance of human papillomavirus infection in different anogenital sites among men and women in Liuzhou, China: A population-based study.
    Int J Cancer. 2018;142:1244-1251.
    PubMed     Abstract available


  291. WRIGHT LB, Schoemaker MJ, Jones ME, Ashworth A, et al
    Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study.
    Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31364.
    PubMed     Abstract available


  292. ABUBAKAR M, Chang-Claude J, Ali HR, Chatterjee N, et al
    Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
    Int J Cancer. 2018 Mar 1. doi: 10.1002/ijc.31352.
    PubMed     Abstract available


    February 2018
  293. CZARNECKI D
    Immigration is the most likely reason for the generational change in melanoma incidence in Queensland, Australia.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31348.
    PubMed    


  294. AITKEN JF, Youlden DR, Baade PD, Soyer HP, et al
    In response to: Immigration is the most likely reason for the generational change in melanoma incidence in Queensland, Australia.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31347.
    PubMed    


  295. LIYANAGE UE, Law MH, Ong JS, Cust AE, et al
    Polyunsaturated fatty acids and risk of melanoma: A Mendelian randomisation analysis.
    Int J Cancer. 2018 Feb 22. doi: 10.1002/ijc.31334.
    PubMed     Abstract available


  296. TER VEER E, Creemers A, de Waal L, van Oijen MGH, et al
    Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in HER2-positive advanced esophagogastric cancer: A meta-analysis.
    Int J Cancer. 2018 Feb 16. doi: 10.1002/ijc.31325.
    PubMed     Abstract available


  297. LAN B, Ma F, Zhai X, Li Q, et al
    The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
    Int J Cancer. 2018 Feb 3. doi: 10.1002/ijc.31291.
    PubMed     Abstract available


    January 2018
  298. SETTE G, Salvati V, Giordani I, Pillozzi E, et al
    Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells.
    Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31260.
    PubMed     Abstract available


  299. BEGG CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, et al
    Contralateral breast cancers: Independent cancers or metastases?
    Int J Cancer. 2018;142:347-356.
    PubMed     Abstract available


  300. LI B, Wang Y, Xu Y, Liu H, et al
    Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival.
    Int J Cancer. 2018 Jan 4. doi: 10.1002/ijc.31243.
    PubMed     Abstract available


  301. BASU P, Ponti A, Anttila A, Ronco G, et al
    Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
    Int J Cancer. 2018;142:44-56.
    PubMed     Abstract available


    December 2017
  302. ANDERSON C, Engel SM, Anders CK, Nichols HB, et al
    Live birth outcomes after adolescent and young adult breast cancer.
    Int J Cancer. 2017 Dec 21. doi: 10.1002/ijc.31227.
    PubMed     Abstract available


  303. MARTIN CA, Cullinane C, Kirby L, Abuhammad S, et al
    Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance.
    Int J Cancer. 2017 Dec 15. doi: 10.1002/ijc.31220.
    PubMed     Abstract available


  304. CHEN J, Yao Q, Huang M, Wang B, et al
    A Randomized Phase III Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-Line Therapy for Patients with Breast Cancer (CBCRT01).
    Int J Cancer. 2017 Dec 14. doi: 10.1002/ijc.31217.
    PubMed     Abstract available


  305. XIE X, Tan W, Chen B, Huang X, et al
    Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer.
    Int J Cancer. 2017 Dec 11. doi: 10.1002/ijc.31208.
    PubMed     Abstract available


  306. MA L, Fu Q, Xu B, Zhou H, et al
    Breast cancer-associated mitochondrial DNA haplogroup promotes neoplastic growth via ROS-mediated AKT activation.
    Int J Cancer. 2017 Dec 11. doi: 10.1002/ijc.31207.
    PubMed     Abstract available


  307. GALLAGHER SJ, Gunatilake D, Beaumont KA, Sharp DM, et al
    HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
    Int J Cancer. 2017 Dec 6. doi: 10.1002/ijc.31199.
    PubMed     Abstract available


  308. HUANG L, Qin Y, Zuo Q, Bhatnagar K, et al
    Ezrin mediates both HGF/Met autocrine and non-autocrine signaling-induced metastasis in melanoma.
    Int J Cancer. 2017 Dec 6. doi: 10.1002/ijc.31196.
    PubMed     Abstract available


  309. UGGE H, Udumyan R, Carlsson J, Andren O, et al
    Acne in late adolescence and risk of prostate cancer.
    Int J Cancer. 2017 Dec 4. doi: 10.1002/ijc.31192.
    PubMed     Abstract available


  310. DALLASPEZIA S, Cantamessa S, Benedetti F
    Light Therapy and Mood in Breast Cancer.
    Int J Cancer. 2017 Dec 2. doi: 10.1002/ijc.31188.
    PubMed    


  311. MCKENZIE F, Zietsman A, Galukande M, Anele A, et al
    Drivers of advanced stage at breast cancer diagnosis in the multi-country African Breast Cancer - Disparities in Outcomes (ABC-DO) study.
    Int J Cancer. 2017 Dec 2. doi: 10.1002/ijc.31187.
    PubMed     Abstract available


    November 2017
  312. LEE KR, Hwang IC, Do Han K, Jung J, et al
    Waist circumference and risk of breast cancer in Korean women: A nationwide cohort study.
    Int J Cancer. 2017 Nov 29. doi: 10.1002/ijc.31180.
    PubMed     Abstract available


  313. HIS M, Le Guelennec M, Mesrine S, Boutron-Ruault MC, et al
    Life course evolution of body size and breast cancer survival in the E3N cohort.
    Int J Cancer. 2017 Nov 27. doi: 10.1002/ijc.31177.
    PubMed     Abstract available


  314. CHEN ST, Li X, Han J
    Personal history of non-melanoma skin cancer diagnosis and death from melanoma in women.
    Int J Cancer. 2017 Nov 24. doi: 10.1002/ijc.31176.
    PubMed     Abstract available


  315. JOHANSSON ALV, Andersson TM, Hsieh CC, Jirstrom K, et al
    Tumor characteristics and prognosis in women with pregnancy-associated breast cancer.
    Int J Cancer. 2017 Nov 23. doi: 10.1002/ijc.31174.
    PubMed     Abstract available


  316. BOADA A, Tejera-Vaquerizo A, Ribero S, Puig S, et al
    Reply to prognosis of sentinel lymph node biopsy in patients with thick melanoma by a propensity score matching prospective study.
    Int J Cancer. 2017 Nov 20. doi: 10.1002/ijc.31162.
    PubMed    


  317. KAWADA T
    Prognosis of sentinel lymph node biopsy in patients with thick melanoma by a propensity score matching prospective study.
    Int J Cancer. 2017 Nov 18. doi: 10.1002/ijc.31163.
    PubMed    


  318. SCHAIRER C, Pfeiffer RM, Gadalla SM
    Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.
    Int J Cancer. 2017 Nov 16. doi: 10.1002/ijc.31148.
    PubMed     Abstract available


  319. BRANDT J, Borgquist S, Almgren P, Forsti A, et al
    Thyroid associated genetic polymorphisms in relation to breast cancer risk in the Malmo Diet and Cancer Study.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31156.
    PubMed     Abstract available


  320. WANG Y, Pfeiffer RM, Alsaggaf R, Meeraus W, et al
    Risk of skin cancer among patients with myotonic dystrophy type 1 based on Primary care physician data from the United Kingdom Clinical Practice Research Datalink.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31143.
    PubMed     Abstract available


  321. BARRDAHL M, Canzian F, Gaudet MM, Gapstur SM, et al
    A comprehensive analysis of polymorphic variants in steroid hormone and IGF-1 metabolism and risk of in situ breast cancer: results from the Breast and Prostate Cancer Cohort (BPC3) Consortium.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31145.
    PubMed     Abstract available


  322. AITKEN JF, Youlden DR, Baade PD, Soyer HP, et al
    Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014.
    Int J Cancer. 2017 Nov 6. doi: 10.1002/ijc.31141.
    PubMed     Abstract available


    October 2017
  323. SCHMIDT ME, Wiskemann J, Schneeweiss A, Potthoff K, et al
    Determinants of physical, affective, and cognitive fatigue: During breast cancer therapy and 12 months follow-up.
    Int J Cancer. 2017 Oct 30. doi: 10.1002/ijc.31138.
    PubMed     Abstract available


  324. HIRKO KA, Chai B, Spiegelman D, Campos H, et al
    Erythrocyte membrane fatty acids and breast cancer risk: A prospective analysis in the Nurses' Health Study II.
    Int J Cancer. 2017 Oct 26. doi: 10.1002/ijc.31133.
    PubMed     Abstract available


  325. KEINAN-BOKER L, Levine H, Leiba A, Derazne E, et al
    Adolescent obesity and adult male breast cancer in a cohort of 1,382,093 men.
    Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31121.
    PubMed     Abstract available


  326. YU J, Wang X, Lu Q, Wang J, et al
    Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3beta/beta-catenin/cyclinD1 signaling pathway.
    Int J Cancer. 2017 Oct 19. doi: 10.1002/ijc.31112.
    PubMed     Abstract available


  327. SUROWY H, Varga D, Burwinkel B, Marme F, et al
    A low frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<60 years) and is associated with reduced DNA repair capacity.
    Int J Cancer. 2017 Oct 16. doi: 10.1002/ijc.31105.
    PubMed     Abstract available


  328. JACKLYN G, Howard K, Irwig L, Houssami N, et al
    Impact of extending screening mammography to older women Information to support informed choices.
    Int J Cancer. 2017;141:1540-1550.
    PubMed     Abstract available


  329. ZHAO B, Zhao H
    Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31097.
    PubMed     Abstract available


  330. CONRAD C, Gotte M, Schlomann U, Roessler M, et al
    ADAM8 expression in breast cancer derived metastases: Functional implications on MMP-9 expression and transendothelial migration in breast cancer cells.
    Int J Cancer. 2017 Oct 7. doi: 10.1002/ijc.31090.
    PubMed     Abstract available


  331. STENEHJEM JS, Veierod MB, Nilsen LT, Ghiasvand R, et al
    Anthropometric factors and cutaneous melanoma: Prospective data from the population-based Janus Cohort.
    Int J Cancer. 2017 Oct 6. doi: 10.1002/ijc.31086.
    PubMed     Abstract available


  332. NAGAPRASHANTHA LD, Adhikari R, Singhal J, Chikara S, et al
    Translational Opportunities for Broad-Spectrum Natural Phytochemicals and Targeted Agent Combinations in Breast Cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31085.
    PubMed     Abstract available


  333. PAN R, Zhu M, Yu C, Lv J, et al
    Cancer incidence and mortality: A cohort study in China, 2008-2013.
    Int J Cancer. 2017;141:1315-1323.
    PubMed     Abstract available


    September 2017
  334. BOADA A, Tejera-Vaquerizo A, Ribero S, Puig S, et al
    Sentinel Lymph Node Biopsy vs Observation in Thick Melanoma: A Multicenter Propensity Score Matching Study.
    Int J Cancer. 2017 Sep 27. doi: 10.1002/ijc.31078.
    PubMed     Abstract available


  335. THAPA B, Bahadur Kc R, Uludag H
    Novel Targets for Sensitizing Breast Cancer Cells to TRAIL-Induced Apoptosis with siRNA Delivery.
    Int J Cancer. 2017 Sep 27. doi: 10.1002/ijc.31079.
    PubMed     Abstract available


  336. GABELLINI C, Gomez-Abenza E, Ibanez-Molero S, Tupone MG, et al
    Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model.
    Int J Cancer. 2017 Sep 26. doi: 10.1002/ijc.31075.
    PubMed     Abstract available


  337. WILKE CM, Hess J, Klymenko SV, Chumak VV, et al
    Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation exposure in post-Chernobyl breast cancer.
    Int J Cancer. 2017 Sep 25. doi: 10.1002/ijc.31072.
    PubMed     Abstract available


  338. KORCH C, Hall EM, Dirks WG, Ewing M, et al
    Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31067.
    PubMed     Abstract available


  339. KIMBUNG S, Markholm I, Bjohle J, Lekberg T, et al
    Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: results from the phase 2 PROMIX trial.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31070.
    PubMed     Abstract available


  340. WANG S, Huo D, Kupfer S, Alleyne D, et al
    Genetic variation in the Vitamin D related pathway and breast cancer risk in women of African ancestry in the Root Consortium.
    Int J Cancer. 2017 Sep 10. doi: 10.1002/ijc.31038.
    PubMed     Abstract available


  341. LAGENDIJK M, van Maaren MC, Saadatmand S, Strobbe LJ, et al
    Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients.
    Int J Cancer. 2017 Sep 7. doi: 10.1002/ijc.31034.
    PubMed     Abstract available


    August 2017
  342. BERTRAND KA, Gerlovin H, Bethea TN, Palmer JR, et al
    Pubertal growth and adult height in relation to breast cancer risk in African American women.
    Int J Cancer. 2017 Aug 28. doi: 10.1002/ijc.31019.
    PubMed     Abstract available


  343. WU AH, Vigen C, Butler LM, Tseng CC, et al
    Metabolic conditions and breast cancer risk among Los Angeles County Filipina Americans compared with Chinese and Japanese Americans.
    Int J Cancer. 2017 Aug 26. doi: 10.1002/ijc.31018.
    PubMed     Abstract available


  344. CESPEDES FELICIANO EM, Prentice RL, Aragaki AK, Neuhouser ML, et al
    Methodological Considerations for Disentangling a Risk Factor's Influence on Disease Incidence versus Post-Diagnosis Survival: The Example of Obesity and Breast and Colorectal Cancer Mortality in the Women's Health Initiative.
    Int J Cancer. 2017 Aug 18. doi: 10.1002/ijc.30931.
    PubMed     Abstract available


  345. ZHENG G, Yu H, Hemminki A, Forsti A, et al
    Familial associations of female breast cancer with other cancers.
    Int J Cancer. 2017 Aug 12. doi: 10.1002/ijc.30927.
    PubMed     Abstract available


  346. KVALE R, Myklebust TA, Engholm G, Heinavaara S, et al
    Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013.
    Int J Cancer. 2017 Aug 10. doi: 10.1002/ijc.30924.
    PubMed     Abstract available


  347. WHITE AJ, Weinberg CR, Park YM, D'Aloisio AA, et al
    Sleep characteristics, light at night and breast cancer risk in a prospective cohort.
    Int J Cancer. 2017 Aug 9. doi: 10.1002/ijc.30920.
    PubMed     Abstract available


    July 2017
  348. NILENDU P, Kumar A, Kumar A, Pal JK, et al
    Breast cancer stem cells as last soldiers eluding therapeutic burn: A hard nut to crack.
    Int J Cancer. 2017 Jul 19. doi: 10.1002/ijc.30898.
    PubMed     Abstract available


  349. SANDSVEDEN M, Manjer J
    Selenium and breast cancer risk: A prospective nested case-control study on serum selenium levels, smoking habits and overweight.
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30875.
    PubMed     Abstract available


  350. SANKATSING VDV, van Ravesteyn NT, Heijnsdijk EAM, de Koning HJ, et al
    Reply to Letter to Editor: 'Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands.'
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30873.
    PubMed    


  351. AUTIER P, Boniol M
    Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands.
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30874.
    PubMed    


  352. SCHIROSI L, De Summa S, Tommasi S, Paradiso A, et al
    VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30868.
    PubMed     Abstract available


  353. BARRDAHL M, Rudolph A, Hopper JL, Southey MC, et al
    Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30859.
    PubMed     Abstract available


    June 2017
  354. FELLER A, Schmidlin K, Bordoni A, Bouchardy C, et al
    Socioeconomic and demographic disparities in breast cancer stage at presentation and survival: A Swiss population-based study.
    Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30856.
    PubMed     Abstract available


  355. ALMOZYAN S, Colak D, Mansour F, Alaiya A, et al
    PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
    Int J Cancer. 2017 Jun 14. doi: 10.1002/ijc.30834.
    PubMed     Abstract available


    May 2017
  356. KNIGHT JA, Fan J, Malone KE, John EM, et al
    Alcohol consumption and cigarette smoking in combination: a predictor of contralateral breast cancer risk in the WECARE Study.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30791.
    PubMed     Abstract available


  357. VAN DEN ENDE C, Oordt-Speets AM, Vroling H, van Agt HME, et al
    Benefits and harms of breast cancer screening with mammography in women aged 40-49 years: A systematic review.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30794.
    PubMed     Abstract available


  358. LOLAS HAMAMEH S, Renbaum P, Kamal L, Dweik D, et al
    Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53.
    Int J Cancer. 2017 May 9. doi: 10.1002/ijc.30771.
    PubMed     Abstract available


  359. BEAU AB, Lynge E, Njor SH, Vejborg I, et al
    Benefit-to-harm ratio of the Danish breast cancer screening programme.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30758.
    PubMed     Abstract available


    April 2017
  360. SANKATSING VDV, van Ravesteyn NT, Heijnsdijk EAM, Looman CWN, et al
    The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up.
    Int J Cancer. 2017 Apr 29. doi: 10.1002/ijc.30754.
    PubMed     Abstract available


  361. NARKHEDE AA, Shevde LA, Rao SS
    Biomimetic strategies to recapitulate organ specific microenvironments for studying breast cancer metastasis.
    Int J Cancer. 2017 Apr 25. doi: 10.1002/ijc.30748.
    PubMed     Abstract available


    March 2017
  362. MARTINEZ VG, Crown J, Porter RK, O'Driscoll L, et al
    Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.
    Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30705.
    PubMed     Abstract available


  363. YANG Z, Hackshaw A, Feng Q, Fu X, et al
    Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
    Int J Cancer. 2017 Mar 14. doi: 10.1002/ijc.30691.
    PubMed     Abstract available


  364. BRINTON LA, Awuah B, Clegg-Lamptey JN, Wiafe-Addai B, et al
    Design considerations for identifying breast cancer risk factors in a population-based study in Africa.
    Int J Cancer. 2017 Mar 13. doi: 10.1002/ijc.30688.
    PubMed     Abstract available


  365. PARK YM, White AJ, Nichols HB, O'Brien KM, et al
    The association between metabolic health, obesity phenotype and the risk of breast cancer.
    Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30684.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: